



INVESTMENT OPPORTUNITY

USCIM Fund XLVII  
OncoGenesis LLC

PREFERRED EQUITY  
\$5,500,000

LEARN MORE

## INVESTMENT OVERVIEW

### ONCOGENESIS, INC.

A New Paradigm for Detection of Cervical Cancer

## COMPANY DESCRIPTION

One woman dies every 2 minutes from Cervical Cancer. In 2018, there were 311,000 deaths and 570,000 new cases estimated by the World Health Organization.

Founded in 2008, OncoGenesis is a revolutionary protein-biomarker-based self-collection and detection system for cervical disease that advances point-of-care screening for disease detection and progression. OncoGenesis will fulfill the global need for a better way to screen for cervical cancer addressing needs in both developing AND developed world markets.

Follow-on Point of Care solution, while addressing one of the most urgent third-world healthcare needs, provides a revenue stream for US physicians for in-office testing with immediate results for US market consumption.

## PRODUCT

### The OncoGenesis System

The Company's proposed clinical solution incorporates the following:

- Cervical protein-based biomarker detection
- **iPap™ Personal Collection Device with "CE Mark Approved** which allows patient samples to be accessed nearly anywhere in the world
- **Diagnostic Equipment** for established Lab-Based & Point-of-Care settings

## COMPETITIVE ANALYSIS

A number of competitor products are available, most however, to a greater or lesser extent, leave significant unmet needs in the diagnosis of cervical cancer.

Comparative Cervical Screening Products							
Major Products	Highly Skilled Technical Labor	Lab Required	HPV Present	HPV Post Integration	Instrument Required	Cost	Time to Result
<b>CerMark™ LBS</b>	<b>No</b>	<b>Yes</b>	<b>Yes</b>	<b>Yes</b>	<b>Yes</b>	<b>Low</b>	<b>5-7 hrs</b>
Pap ELISA-E6 & E7	Yes	Yes	Yes	Yes	Yes	Low	Hours to Days
Automated Slide Reader	Yes	Yes	No	No	Yes	Med	Days
Roche Cobas	Yes	Yes	Yes	No	Yes	High	Days
Qiagen (Digene)	Yes	Yes	Yes	No	Yes	High	Days to Weeks
Arbor Vita Assay	No	No	Yes	Yes	No	Med	Rapid

## THE OPPORTUNITY

**Transaction Description:** Seeking to raise ~\$5.5 Million in Equity to manufacture iPap Collectors, and assay kits, complete lab testing and POC sensor development, and finalize Strategic Partner funding as well as other working capital needs.

## DEAL HIGHLIGHTS

Offering Size:	Up to \$5,500,000 in Equity
Offering Type:	Membership Unit
Price Per Unit:	\$20,000
Minimum Purchase Size:	1 Unit (\$20,000)
Company Name:	Oncogenesis, Inc.
Industry:	Medical Device
Headquartered:	Holliston, MA

## MANAGEMENT INFORMATION

**Peter Gombrich, Founder, Executive Chairman**

**Paul Vichi, PhD, Co-Founder, CTO**

**Scott Christensen, CEO**

**Ralph Germschied, VP Sales and Marketing**

**Kevin McCurdy - VP Finance & Administration**



## RISKS & DISCLOSURES

Below mentioned Risk Factors are not exhaustive and the list is only indicative of most significant risks. All other risks are cited in the Private Placement Memorandum.

### High Risk

- Lack of full amount of funding could continue to delay the validation phase of the final product/assay configuration
- Core Dx Contract - Ability to get final agreement signed

### Other Risks

- Company has almost \$1,000,000 in outstanding liabilities and creditors could pursue legal action to collect their debts.

- Limited operating history and substantial need for Funding
- No assurance of when the products will gain market acceptance
- Dependence on Agreements with Distributors and/or Licensees/Joint Ventures
- Technological Change may render product obsolete
- Clinical Trial and Regulatory approval
- Reliance on key personnel
- Dependence on service providers
- No Public Market for shares
- The risk of losses resulting from inadequate or failed internal processes, people and systems, or from external events

If you would like to know more about how your business can secure the funding it needs, visit [www.uscapglobal.com](http://www.uscapglobal.com) or call +1 415 889 1010



Follow us [/uscapglobal](https://www.uscapglobal.com)